Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 5/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.40 |
| ▸ | PTGES | O14684 | 8/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9898570 | 0.89 | EPHX2 (0.39) | EPHX2NR1H4PTGESRIPK1 | |
| SCHEMBL9899035 | 0.88 | CA1 (0.42) | EPHX2NR1H4PTGESHDAC6 | |
| SCHEMBL670974 | 0.79 | IDO1 (0.43) | EPHX2NR1H4PTGESHDAC6 | |
| SCHEMBL9898267 | 0.77 | EPHX2 (0.40) | EPHX2NR1H4PTGESRIPK1HDAC6 | |
| SCHEMBL9898822 | 0.77 | EPHX2 (0.37) | EPHX2NR1H4PTGESP2RX7 | |
| SCHEMBL671339 | 0.76 | DGAT1 (0.40) | EPHX2NR1H4PTGESP2RX7 | |
| SCHEMBL9944728 | 0.75 | EPHX2 (0.36) | EPHX2NR1H4PTGESP2RX7RIPK1 | |
| SCHEMBL15827311 | 0.75 | EPHX2 (0.43) | EPHX2NR1H4PTGESP2RX7RIPK1 | |
| SCHEMBL15827310 | 0.73 | PTGES (0.42) | EPHX2NR1H4PTGESHDAC6 | |
| SCHEMBL12799942 | 0.71 | EPHX2 (0.39) | EPHX2NR1H4PTGESRIPK1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8674113-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-03-18 | — | — | US | disclosed |
| US-8674113-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-03-18 | — | — | US | disclosed |
| US-8674113-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-03-18 | — | — | US | disclosed |
| US-20120149676-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-14 | — | — | US | disclosed |
| US-20120149676-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-14 | — | — | US | disclosed |
| US-20120149676-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-14 | — | — | US | disclosed |
| WO-2012076673-A1 | 6-AMINO-2-PHENYLAMINO-1H-BENZIMIDAZOLE-5-CARBOXAMIDE- DERIVATIVES AND THEIR USE AS MICROSOMAL PROSTAGLANDIN E2 SYNTHASE-1 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149676-A1 | NOVEL COMPOUNDS | PTGS1, PTGER1, PTGES | EPHX2 193/4885NR1H4 443/4885PTGES 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.